{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:05:03Z","timestamp":1777917903801,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumori"],"published-print":{"date-parts":[[2004,5]]},"abstract":"\n Aims and background<\/jats:title>\n A dose-dense therapy with weekly paclitaxel given as a 1-hr infusion yielded a 53% overall response rate in breast cancer patients resistant to anthracyclines, with a remarkable lack of neutropenia (Seidman, 1998). We performed a monoinstitutional phase II trial in order to confirm these interesting results.<\/jats:p>\n <\/jats:sec>\n \n Patients and methods<\/jats:title>\n \n Eligibility criteria included advanced breast cancer and no taxane pretreatment. Paclitaxel was administered weekly at the dose of 90 mg\/m\n 2<\/jats:sup>\n (60 mg\/m\n 2<\/jats:sup>\n in patients at high risk of toxicity) by 1-hr iv infusion. Fifty-eight patients entered the trial. Median age was 54 years (range, 38-72). Performance status was good (median 1; range, 0-2). Fifty-two patients were pretreated with anthracyclines.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 1,004 weekly paclitaxel infusions were administered (median, 19 per patient; range, 4-43). The median delivered dose intensity was 67.4 mg\/m\n 2<\/jats:sup>\n \/week (range, 43-86). Twenty-eight of the 58 assessable patients obtained an objective response (48%), 15 had stable disease (26%) and 15 progressed (26%). The overall response rate was 48% (95% confidence interval, 35-61%) with 5 complete responses (8%). In anthracycline-pretreated patients, 23\/52 (44%) responses were observed. Median duration of response was 5 months (range, 3-27). Toxicity was acceptable apart from a case of pulmonary embolism in a 70-year-old patient, 1 case of congestive heart failure in an anthracycline-pretreated patient aged 64, and 9 cases of G3 neutropenia. Peripheral neuropathy was observed in 38 patients (64%), usually of a mild grade; alopecia in 45 patients (78%) and onychopathy in 16 (28%), usually of a mild grade apart from 2 cases requiring treatment interruption. Tachycardia and atrial fibrillation occurred in a 55-year-old woman.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Our data seem to confirm the activity and safety of this approach even in a heavily pretreated population of patients. Its combination with other active drugs needs to be further investigated in clinical trials.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/030089160409000304","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T11:23:33Z","timestamp":1524482613000},"page":"285-288","source":"Crossref","is-referenced-by-count":34,"title":["Long-Term, weekly One-Hour Infusion of Paclitaxel in Patients with Metastatic Breast Cancer: A Phase II Monoinstitutional Study"],"prefix":"10.1177","volume":"90","author":[{"given":"Davide","family":"Lombardi","sequence":"first","affiliation":[{"name":"Division of Medical Oncology C, Centro di Riferimento Oncologico, Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Crivellari","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology C, Centro di Riferimento Oncologico, Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Scuderi","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology C, Centro di Riferimento Oncologico, Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Donatella","family":"Magri","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology C, Centro di Riferimento Oncologico, Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Spazzapan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology C, Centro di Riferimento Oncologico, Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Sorio","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology C, Centro di Riferimento Oncologico, Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Di Lauro","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology C, Centro di Riferimento Oncologico, Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Scalone","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology C, Centro di Riferimento Oncologico, Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Veronesi","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology C, Centro di Riferimento Oncologico, Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2004,5,1]]},"reference":[{"key":"bibr1-030089160409000304","first-page":"2349","volume-title":"Cancer medicine","author":"Fisher B.","year":"1997"},{"key":"bibr2-030089160409000304","first-page":"3","volume":"25","author":"Paridaens R.","year":"1998","journal-title":"Semin Oncol"},{"key":"bibr3-030089160409000304","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.5.1152"},{"key":"bibr4-030089160409000304","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.15.1169"},{"key":"bibr5-030089160409000304","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.8.2056"},{"key":"bibr6-030089160409000304","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.8.1621"},{"key":"bibr7-030089160409000304","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00641-9"},{"key":"bibr8-030089160409000304","first-page":"146","volume":"16","author":"Seidman A.D.","year":"1997","journal-title":"Proc ASCO"},{"key":"bibr9-030089160409000304","first-page":"143","volume-title":"The molecular basis of cancer","author":"Gilwski T.","year":"1995"},{"key":"bibr10-030089160409000304","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"bibr11-030089160409000304","first-page":"128","volume":"23","author":"Glantz M.J.","year":"1996","journal-title":"Semin Oncol"},{"key":"bibr12-030089160409000304","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"bibr13-030089160409000304","first-page":"126","volume":"18","author":"Perez E.A.","year":"1999","journal-title":"Proc ASCO"},{"key":"bibr14-030089160409000304","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.15.3500"}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089160409000304","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089160409000304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:25:36Z","timestamp":1777659936000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/030089160409000304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["10.1177\/030089160409000304"],"URL":"https:\/\/doi.org\/10.1177\/030089160409000304","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}